Trevena Inc is a biopharmaceutical company that focuses on developing innovative therapies to treat various central nervous system disorders and acute pain conditions. The company leverages its proprietary drug discovery platform to create novel molecules that target specific receptors in the brain and nervous system, aiming to provide safer and more effective treatment options. By prioritizing patient safety and reducing reliance on opioids, Trevena is actively exploring advanced therapies that can improve the quality of life for patients suffering from difficult-to-treat medical conditions. Read More
SAN MATEO, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the appointments of two biotechnology industry leaders, Anne Phillips and Jennifer Jarrett, to the board of directors of the Company, effective August 1, 2024.
Trevena shares dropped 33.7% to $0.23 with a session volume of 23.65 million. Notably, TRV045 did not cause S1P1R desensitization or protein reduction, unlike fingolimod.
